TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1556284

Group type: EXPERIMENTAL
Intervention: Four-session training group (n = 29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n = 31)
Number of subjects: 60
Study: 2861527

Group type: EXPERIMENTAL
Intervention: Triamterene (50 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Amiloride (5 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Triamterene-containing combination diuretic
Number of subjects: 26
Study: 30901079

Group type: EXPERIMENTAL
Intervention: Evofinder® system
Number of subjects: 1000
Study: 29193093

Group type: EXPERIMENTAL
Intervention: Morning fasting (FAST; 0 kcal until 12.00 h)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Daily breakfast consumption (BFAST; ≥700 kcal before 11.00 h)
Number of subjects: 49
Study: 26199116

Group type: EXPERIMENTAL
Intervention: Information leaflet provided before UDS
Number of subjects: 104

Group type: COMPARATOR
Intervention: No information leaflet provided before UDS
Number of subjects: 104
Study: 23656841

Group type: EXPERIMENTAL
Intervention: Levomilnacipran SR (75 mg or 100 mg)
Number of subjects: 553

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study: 21115317

Group type: EXPERIMENTAL
Intervention: Standardized teaching method
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 18
Study: 19356393

Group type: EXPERIMENTAL
Intervention: Controlled release cyclobenzaprine tablet (20 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Controlled release cyclobenzaprine tablet (20 mg) with high fat meal
Number of subjects: 36

Group type: COMPARATOR
Intervention: Immediate release cyclobenzaprine tablet (10 mg)
Number of subjects: 36
Study: 17239355

Group type: EXPERIMENTAL
Intervention: D-amphetamine 20 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: D-amphetamine 10 mg
Number of subjects: 99
Study: 15534477

Group type: EXPERIMENTAL
Intervention: Non-penetrating deep sclerectomy (NPDS)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Phaco-Non-penetrating deep sclerectomy (phaco-NPDS)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Punch trabeculectomy (PT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Phaco-Punch trabeculectomy (phaco-PT)
Number of subjects: 65
Study: 11119472

Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients with obstructive coronary artery disease (n = 30)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Type 2 diabetic patients without obstructive coronary artery disease (n = 12)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Non-diabetic patients with obstructive coronary artery disease (n = 28)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Non-diabetic patients without obstructive coronary artery disease (n = 13)
Number of subjects: 83
Study: 9039834

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (30 mg betaC/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8174049

Group type: EXPERIMENTAL
Intervention: 25 mg/kg etidronate disodium for 24 hours
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30 mg/kg etidronate disodium for 24 hours
Number of subjects: 30
Study: 2974417

Group type: EXPERIMENTAL
Intervention: procaterol
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 31842246

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (COLD)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9
Study: 29540217

Group type: EXPERIMENTAL
Intervention: Linagliptin once daily
Number of subjects: 6980

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6980
Study: 28746231

Group type: EXPERIMENTAL
Intervention: Epidermal Growth Factor (EGF)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Fibroblast Growth Factor-2 (FGF-2)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.3% (w/v) Ofloxacin drops
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conservative observation
Number of subjects: 180
Study: 26439936

Group type: EXPERIMENTAL
Intervention: 1% iodopovidone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2% iodopovidone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both doses of iodopovidone
Number of subjects: 60
Study: 23399437

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 8844

Group type: EXPERIMENTAL
Intervention: CT-colonography
Number of subjects: 8844

Group type: COMPARATOR
Intervention: Colonoscopy non-screenees
Number of subjects: 8844

Group type: COMPARATOR
Intervention: CT-colonography non-screenees
Number of subjects: 8844
Study: 21358397

Group type: EXPERIMENTAL
Intervention: Closed suction systems
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Open suction systems
Number of subjects: 1110
Study: 18489219

Group type: EXPERIMENTAL
Intervention: Participants told they would be able to smoke during the study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants who anticipated having to wait several hours before smoking
Number of subjects: 0
Study: 21344051

Group type: EXPERIMENTAL
Intervention: Provent® nasal valve device
Number of subjects: 20
Study: 15754270

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 12142108

Group type: EXPERIMENTAL
Intervention: N-terminal pro brain natriuretic peptide (NT-proBNP) measurement on admission
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: NT-proBNP measurement combined with clinical background factors, ECG, and troponin T
Number of subjects: 755
Study: 9519233

Group type: EXPERIMENTAL
Intervention: Multidose powder inhaler
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reservoir device
Number of subjects: 10
Study: 8079925

Group type: EXPERIMENTAL
Intervention: Radionuclide studies
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Videofluoroscopic studies
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Combined radionuclide and videofluoroscopic studies
Number of subjects: 77

Group type: COMPARATOR
Intervention: Manometry
Number of subjects: 77
Study: 2511911

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily plus Atenolol 50 mg twice daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg twice daily plus Atenolol 50 mg twice daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Atenolol 50 mg twice daily
Number of subjects: 18
Study: 12618533

Group type: EXPERIMENTAL
Intervention: Low-dose ACTH
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-dose ACTH
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy comparison subjects (control)
Number of subjects: 36
Study: 31790665

Group type: EXPERIMENTAL
Intervention: Hand‐holding a cellular phone to answer a call from investigators
Number of subjects: 47
Study: 29908688

Group type: EXPERIMENTAL
Intervention: Honey (70 g per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sucrose (70 g per day)
Number of subjects: 60
Study: 27703294

Group type: EXPERIMENTAL
Intervention: Lisinopril/Hydrochlorothiazide
Number of subjects: 270
Study: 24779731

Group type: EXPERIMENTAL
Intervention: Two drug combinations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 22665030

Group type: EXPERIMENTAL
Intervention: Household contacts of pediatric patients with S aureus colonization and SSTI
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Household contacts (parents)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Methicillin-resistant S aureus (MRSA)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Methicillin-sensitive S aureus (MSSA)
Number of subjects: 609
Study: 21029610

Group type: EXPERIMENTAL
Intervention: Group A: osteoform 1000 mg/d + alfacalcidol 0.25 µg/bid orally
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Group B: osteoform 1000 mg/d + alfacalcidol 0.25 µg/bid + tibolone 1.25 mg/d orally
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Group C: osteoform 1000 mg/d + alfacalcidol 0.25 µg/bid + bisphosphonates 70 mg/w orally
Number of subjects: 109

Group type: COMPARATOR
Intervention: Group A
Number of subjects: 109

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 109

Group type: COMPARATOR
Intervention: Group C
Number of subjects: 109
Study: 19077238

Group type: EXPERIMENTAL
Intervention: Individual auditory cueing device
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no auditory cueing device)
Number of subjects: 47
Study: 15960573

Group type: EXPERIMENTAL
Intervention: Luteal phase dosing of escitalopram (10-20 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Symptom-onset dosing of escitalopram (10-20 mg/day)
Number of subjects: 27
Study: 12907109

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with 0.25% bupivacaine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous meperidine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 200
Study: 10596559

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (0.15 mg infusion 15 minutes before operation)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intramuscular clonidine (0.15 mg 60-90 minutes before operation)
Number of subjects: 21
Study: 7552519

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zalcitabine (ddC)
Number of subjects: 0
Study: 1781761

Group type: EXPERIMENTAL
Intervention: Mometasone furoate cream 0.1% applied once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Betamethasone dipropionate cream 0.05% applied twice daily
Number of subjects: 0
Study: 6797754

Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate (0.1%)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sodium cromoglycate (2%)
Number of subjects: 39
Study: 30621789

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 577
Study: 29577512

Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT) in addition to standard treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Delayed CRT group
Number of subjects: 80
Study: 26943500

Group type: EXPERIMENTAL
Intervention: Supplementary oral immunonutrition (IN) (Oral Impact®, Nestlé) to reach a goal of 1.5 g protein/kg BW, administered for seven days before surgery.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group continued their habitual diet.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Supplementary oral immunonutrition (IN) (Oral Impact®, Nestlé)
Number of subjects: 35
Study: 24475144

Group type: EXPERIMENTAL
Intervention: Souvenaid
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 179
Study: 23212429

Group type: EXPERIMENTAL
Intervention: Self-reported depression
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Modified Zung Depression Index (MZDI)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Modified Somatic Perception Questionnaire (MSPQ)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Correlation of MZDI and MSPQ scores
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Correlation with LBP severity and back-specific disability
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Correlation with number of key osteopathic lesions
Number of subjects: 202
Study: 20113921

Group type: EXPERIMENTAL
Intervention: Motivational Behavioral Intervention (MBI) plus standard care
Number of subjects: 376

Group type: COMPARATOR
Intervention: Standard Care (SC) alone
Number of subjects: 376
Study: 18042501

Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI)
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: PI+NNRTI
Number of subjects: 1360

Group type: COMPARATOR
Intervention: No virologic failure (control group)
Number of subjects: 1360
Study: 16125661

Group type: EXPERIMENTAL
Intervention: 55 IU ovine hyaluronidase
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: 75 IU ovine hyaluronidase
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 1125
Study: 12141723

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11206234

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (two sprays per nostril twice daily, 1.1 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 0
Study: 9641928

Group type: EXPERIMENTAL
Intervention: Flutamide (Drogenil)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Flutamide (Drogenil) with 6 week exclusions
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo with 6 week exclusions
Number of subjects: 49
Study: 7978687

Group type: EXPERIMENTAL
Intervention: Technetium-99m (Tc) pyrophosphate scanning
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no Tc scan)
Number of subjects: 15
Study: 2645030

Group type: EXPERIMENTAL
Intervention: 5 per cent acyclovir ointment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 409597

Group type: EXPERIMENTAL
Intervention: 1% HEDP containing toothpaste
Number of subjects: 50
Study: 30677038

Group type: EXPERIMENTAL
Intervention: Seropositivity to cysticercal antigens
Number of subjects: 3696
Study: 29187313

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN) of the lumbar multifidus
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sham-Dry Needling (sham-DN)
Number of subjects: 47
Study: 25535358

Group type: EXPERIMENTAL
Intervention: Reading an LE‐eBook
Number of subjects: 1508

Group type: COMPARATOR
Intervention: Reading a printed book
Number of subjects: 1508
Study: 23819410

Group type: EXPERIMENTAL
Intervention: Traction of the cervical spine following collar zone massage with soft cervical collar
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Combined physiotherapeutic treatment including collar zone massage, orthotraction therapy, and soft cervical collar
Number of subjects: 65
Study: 21683020

Group type: EXPERIMENTAL
Intervention: Education DVD
Number of subjects: 509

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 509
Study: 19538331

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 40
Study: 17144492

Group type: EXPERIMENTAL
Intervention: Human thrombin insufflated locally on the right side
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physiological saline insufflated on the left side
Number of subjects: 80
Study: 15574092

Group type: EXPERIMENTAL
Intervention: Squat Whole Body Vibration (SWBV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional Squats (S)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both groups (SWBV and S)
Number of subjects: 14
Study: 11413406

Group type: EXPERIMENTAL
Intervention: Chen Medium (CM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Optisol GS
Number of subjects: 20
Study: 9117021

Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (NO2) exposure (490 micrograms/m3)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Purified air exposure
Number of subjects: 18
Study: 8345288

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate (LE) 0.5% suspension, 1 drop 4 times daily for 42 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisolone acetate (PA) 1.0%, 1 drop 4 times daily for 42 days
Number of subjects: 0
Study: 3731678

Group type: EXPERIMENTAL
Intervention: 75 mg PPA (sustained-release preparation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30724693

Group type: EXPERIMENTAL
Intervention: Serious Illness Conversation Guide training for clinicians
Number of subjects: 25
Study: 29861230

Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization (IASTM) treatments (six treatments over three weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study: 26681713

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 25284194

Group type: EXPERIMENTAL
Intervention: 100 μg of sodium selenite once daily for 365 consecutive days
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 21862454

Group type: EXPERIMENTAL
Intervention: Low-GDP PDF (Balance®; Fresenius Medical Care)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conventional PDF (Stay safe®; Fresenius Medical Care)
Number of subjects: 152
Study: 20814325

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Osmotic-release oral system methylphenidate (OROS MPH)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) with dose escalation to 30 mg per 9 hours
Number of subjects: 64

Group type: COMPARATOR
Intervention: Osmotic-release oral system methylphenidate (OROS MPH) with dose escalation to 54 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) and OROS MPH
Number of subjects: 64
Study: 17650795

Group type: EXPERIMENTAL
Intervention: Fuzheng Jiedu Granule (FJG) plus Western medicine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 60
Study: 16131620

Group type: EXPERIMENTAL
Intervention: Situational constraints reflecting plausible motives for essay writing behavior
Number of subjects: 0

Group type: COMPARATOR
Intervention: Situational constraints (perceptually increasing salience)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No-choice condition essays
Number of subjects: 0
Study: 14634543

Group type: EXPERIMENTAL
Intervention: 1.0 mg transdermal estradiol
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: 1.5 mg transdermal estradiol
Number of subjects: 148
Study: 10567197

Group type: EXPERIMENTAL
Intervention: 12 degrees passive head-up tilt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 degrees passive head-up tilt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 53 degrees passive head-up tilt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 70 degrees passive head-up tilt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 0
Study: 8530994

Group type: EXPERIMENTAL
Intervention: Real low-level laser (LLL) treatment (4 x 6 J per treatment, total of 20 treatments)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo low-level laser treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Real low-level laser (LLL) treatment
Number of subjects: 13
Study: 1824798

Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (HD MAP) 1,000 mg b.i.d. p.o.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oophorectomy (OPX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oophorectomy (OPX) after progression from HD MAP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (HD MAP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (HD MAP) and Oophorectomy (OPX)
Number of subjects: 40
Study: 6343871

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 3064
Study: 4087291

Group type: EXPERIMENTAL
Intervention: Riboflavin 5 mg dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Larger doses of riboflavin
Number of subjects: 0
Study: 29335751

Group type: EXPERIMENTAL
Intervention: tDCS (2.0 mA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 26526444

Group type: EXPERIMENTAL
Intervention: Pathological Internet Use (PIU) assessed using the Young Diagnostic Questionnaire (YDQ)
Number of subjects: 1444

Group type: EXPERIMENTAL
Intervention: Previous PIU symptoms and emotional problems
Number of subjects: 1444
Study: 24753478

Group type: EXPERIMENTAL
Intervention: Nonivamide treatment (NT) - 0.15 mg nonivamide added to 75 g glucose in 300 mL water
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control treatment (CT) - 75 g glucose in 300 mL water
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nonivamide treatment (NT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control treatment (CT)
Number of subjects: 24
Study: 23536015

Group type: EXPERIMENTAL
Intervention: Breast cancer survivors treated with chemotherapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Age-matched female controls
Number of subjects: 19
Study: 19887889

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Supportive-experiential group therapy
Number of subjects: 348

Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 348
Study: 19061748

Group type: EXPERIMENTAL
Intervention: Single walking trials
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Continuous walking trials
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Single walking trials (young women)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Single walking trials (older women)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Continuous walking trials (young women)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Continuous walking trials (older women)
Number of subjects: 27
Study: 16607076

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11447732

Group type: EXPERIMENTAL
Intervention: GnRH-agonist leuprorelin acetate depot (LAD) 3.75 mg subcutaneously per month
Number of subjects: 48

Group type: COMPARATOR
Intervention: Gestagen lynestrenol (LYN) 5 mg orally twice per day
Number of subjects: 48
Study: 9675561

Group type: EXPERIMENTAL
Intervention: FSH-HP
Number of subjects: 120

Group type: COMPARATOR
Intervention: FSH-HP + hMG
Number of subjects: 120
Study: 8033761

Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg on Days 1 and 3, and 150 mg on Day 5)
Number of subjects: 38
Study: 2557869

Group type: EXPERIMENTAL
Intervention: Mouthrinse containing soluble pyrophosphate and a copolymer of methoxyethylene and maleic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mouthrinse containing only soluble pyrophosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 0